Product title
Vendor
$19.99 | $24.99
Product title
Vendor
$19.99 | $24.99
Product title
Vendor
$19.99 | $24.99
Product title
Vendor
$19.99 | $24.99
Supports Pulmonary Edema Management in Dogs
Product Description
UpCard®-CA1 is a once-daily oral torsemide solution formulated specifically for dogs with congestive heart failure caused by myxomatous mitral valve disease (MMVD). As a loop diuretic, it helps manage pulmonary edema by promoting controlled fluid removal. Designed for use alongside pimobendan, spironolactone, and an ACE inhibitor, it offers high oral bioavailability and is conditionally approved by the FDA for long-term management under veterinary supervision.
Benefits
- Once-Daily Dosing: Administered orally once daily, supporting convenient long-term management of stable CHF cases.
- High Bioavailability: Demonstrates approximately 96% bioavailability, supporting consistent systemic exposure following oral administration.
- Targeted Diuretic Action: Inhibits the Na+/2Cl-/K+ transporter in the loop of Henle to promote effective fluid removal.
- Proven Field Response: Achieved a 96% treatment success rate at Day 84 in evaluated stable MMVD cases.
- Flexible Administration: May be given with or without food, offering adaptable dosing options for individual patients.
Ingredients
Active Ingredients
Torsemide (2 mg/ml; 0.2% w/v)
Inactive Ingredients
Tromethamine, hydroxyethyl cellulose, saccharin sodium, propylene glycol.
How to Use
Recommended-Dosage Chart
|
Body Weight Basis |
Torsemide Dose |
Oral Solution Volume |
|
Per lb body weight |
0.05–0.2 mg/lb |
0.025–0.1 ml/lb |
|
Per kg body weight |
0.11–0.44 mg/kg |
0.055–0.22 ml/kg |
Maximum Dose: Do not exceed 0.2 mg/lb (0.44 mg/kg) per day, equivalent to 0.1 ml/lb (0.22 ml/kg).
Dosage & Administration Instructions
- Once Daily Dosing: Give orally once a day within the recommended dose range based on body weight.
- Concurrent Therapy: Use with pimobendan, spironolactone, and an ACE inhibitor for managing CHF when indicated.
- Stable Patients Only: Intended for clinically stable dogs with MMVD, not for emergency pulmonary edema cases.
- Dose Adjustments: Adjust dosage in 25% increments under veterinary supervision within the recommended limits.
- Monitoring Required: Check hydration, BUN, creatinine, and electrolytes before and after making therapy adjustments.
- Food Flexibility: Can be given with or without food, based on veterinary guidance.
- Prescription Required: Federal law limits this medication to use by or on the order of a licensed veterinarian.
Disclaimer: This dosage information is provided by the manufacturer. Always consult your veterinarian before administering or adjusting any supplement for your pet.
Additional Information
Precautions
- Not Emergency Use: Not indicated for dogs requiring immediate injectable diuretic therapy for an acute crisis.
- Pre-Treatment Assessment: Correct dehydration and electrolyte abnormalities prior to initiating therapy.
- Renal Monitoring: Regularly monitor BUN, creatinine, and electrolytes, especially during early treatment stages.
- Drug Interactions: Use caution with NSAIDs, aminoglycosides, cephalosporins, corticosteroids, and cardiac glycosides.
- Limited Evaluations: Safety not evaluated in congenital heart disease, diabetes, breeding, pregnant, or lactating dogs.
- Sulfonamide Sensitivity: May induce allergic reactions in dogs with known sulfonamide allergies.
Possible Side Effects
- Increased Urination: Polyuria and polydipsia often occur during torsemide treatment.
- Renal Changes: There may be increased BUN, serum creatinine, and a higher risk of kidney problems.
- Electrolyte Imbalance: Hypokalemia, hypochloremia, hypercalcemia, and hypomagnesemia can happen during treatment.
- Digestive Upset: Some dogs may experience vomiting, diarrhea, and a reduced appetite.
- Lethargy Signs: A decrease in activity or signs of lethargy may be seen in some dogs.
- Worsening CHF: Clinical studies have reported cough, dyspnea, pulmonary edema, and cardiac arrest.
Storage Information
- Temperature Limit: Store at or below 30°C (86°F).
- Temperature Excursions: Excursions permitted between 4°C and 40°C (39°F and 104°F).
- Discard Timeline: Discard bottle 90 days after first opening.
- Secure Storage: Keep in a secure location out of reach of pets and children.
Shipping & Return
We offer ground, express, priority, and international delivery; see our shipping policy for details.
For return instructions or product concerns, please refer to our detailed refund policy.
Prescription items are NON-RETURNABLE and NON-REFUNDABLE.
Frequently Asked Questions
Q1: What is UpCard®-CA1 used for in dogs?
Ans: UpCard®-CA1 is prescribed to manage pulmonary edema in dogs with congestive heart failure from myxomatous mitral valve disease (MMVD). It is for stable patients and should be given with pimobendan, spironolactone, and an ACE inhibitor under the supervision of a veterinarian.
Q2: How is UpCard®-CA1 dosed for dogs?
Ans: UpCard®-CA1 is administered orally once daily at 0.05–0.2 mg per pound (0.11–0.44 mg/kg) of body weight. The maximum recommended dose is 0.2 mg/lb (0.44 mg/kg) per day. Dose adjustments should be made in 25% increments under veterinary guidance.
Q3: Can UpCard®-CA1 be given with food?
Ans: UpCard®-CA1 can be given with or without food. Feeding has been shown to raise overall drug exposure (AUC) by about 24%, but it does not significantly change the peak concentration. Your veterinarian will decide the best way to give it to your dog.
Q4: What monitoring is required while using UpCard®-CA1?
Ans: Dogs receiving UpCard®-CA1 require regular monitoring of hydration status, blood urea nitrogen (BUN), serum creatinine, and electrolyte levels. Assessments should be performed before starting therapy, within 24 and 48 hours after initiation or dose adjustments, and periodically thereafter as directed by a veterinarian.
Q5: What are the most common side effects of UpCard®-CA1?
Ans: The most commonly reported adverse reactions include increased urination, increased thirst, elevated BUN and creatinine, and electrolyte disturbances such as hypokalemia. Gastrointestinal signs like vomiting or diarrhea and lethargy have also been reported. Renal insufficiency may occur and requires veterinary monitoring.